We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Puretech Health Plc | PRTC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 5.00 | 2.34% | 219.00 | 16:29:47 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 214.00 | 214.00 | 224.50 | 219.00 | 214.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 16/4/2024 12:35 by chazzyt What has Puretech got to do to interest investors.Nothing has shaken the tree in years.Zohar moving on has upset long term investors and the 2 50 offer is embarrassing.The Peel Hunt boys must be on the wakky bakky |
Posted at 15/4/2024 12:16 by crazycoops I just picked this up from Mark Simpson on Stockopedia. To avoid withholding tax on a tender offer from a US based company, investors will need to complete a Section 302 "Certification of Treatment of Tender Payment" form. This is separate from a W-8BEN form that most investors will already be familiar with. Worth noting for anyone considering taking up the PRTC tender offer. |
Posted at 09/4/2024 08:12 by takeiteasy That would be really nice Colin.Perhaps someone needs to start training sessions for professional UK investors in how biotech works as an industry if so many biotechs are so poorly understood these days ? Not sure what else we can do when a number of these scenarios arise all over the place.. |
Posted at 16/3/2024 16:37 by colinblackbourn 27 September 2023PureTech Health plcPureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases , today announced the appointment of Robert Lyne as Chief Portfolio Officer. Robert brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience. Robert is expected to join PureTech by early January 2024."We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients," said Daphne Zohar, Founder and Chief Executive Officer of PureTech. "His extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech's own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties."Mr. Lyne joins PureTech from Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as General Counsel and Chief Operating Officer before being appointed Chief Executive Officer in April 2021. He began his career as a lawyer at international law firm Bird & Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. He has worked on over 80 venture capital financings in Europe and North America as well as multiple trade exits and IPOs. As an experienced UK plc executive, Mr. Lyne has broad experience formulating and implementing corporate strategy. Mr. Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University."I am delighted to be joining the management team at PureTech during such an exciting time in the Company's growth," said Mr. Lyne. "As pioneers of the hub-and-spoke model in the biotechnology sector, PureTech's approach is aligned with my own experience and ambitions. They are highly innovative in their approach to both science and business, which has led to the team delivering an impressive track record of developing new therapies with transformational potential. I look forward to working with the skilled team at PureTech and its outstanding network of advisors to further drive the Company forward." |
Posted at 16/3/2024 12:58 by colinblackbourn Karuna $14bn closing frees up cash from the big holders.Fidelity will have made several billion dollars for example.100pc owned Seaport and Gallop will be looking for investors ahead of eventual IPO..Remember Seaport is 'Karuna on Steroids'.both ultimate valuations in for free.I wonder what the share price will be by the final results at the end of April. |
Posted at 10/2/2024 15:48 by takeiteasy If one large investor wants to sell a load and two others are happy to buy this load then why not do a single cross trade and switch them over - this constant dripping of small sells each day to achieve the same result seems very odd tbh. |
Posted at 10/2/2024 09:30 by colinblackbourn There has been NO RNS to explain that Puretech will be receiving $294m.Yes it's on the Corporate Deck but you have to look hard to find it.The Company needs to change its approach to private investors.https://pu |
Posted at 10/2/2024 09:07 by takeiteasy Thanks Colin, there was me thinking the stock overhang was cleared quite some while back :) very helpful to understand what the bigger players are up to and as you say they must nearly be done. I thought CS was a share dealer/broker and not investor so intrigued why they might have owned a stock like this but not at all suprised to see them out of here. |
Posted at 07/2/2024 17:37 by crazycoops A nice write up on PRTC by private investor Chris Archer hTTps://uksmallcapst |
Posted at 10/1/2024 07:41 by takeiteasy There is a very interesting narrative in the BBH trust monthly update today about why 2023 went so horribly wrong for even the best biotechs - nothing we don't know of course but a useful reminder of the impact of certain key issues on investor sentiment.This stock feels like it is being very tightly controlled, tiny move by tiny move to avoid any jumps for short term traders to join the party. Just my hunch but we seem to be heading in the right direction at the moment little by little...dyor etc |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
